4.8 Article

Public T cell receptors confer high-avidity CD4 responses to HIV controllers

Journal

JOURNAL OF CLINICAL INVESTIGATION
Volume 126, Issue 6, Pages 2093-2108

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI83792

Keywords

-

Funding

  1. ANRS
  2. Sidaction
  3. Pasteur Institute
  4. Australian Research Council (ARC)
  5. National Health and Medical Research Council of Australia (NHMRC)
  6. ANRS [EP36-8]
  7. Agence Nationale de la Recherche (ANR) [PD1VAX]
  8. ARC [FF120100416]
  9. NHMRC Australia [AF50]
  10. Fondation pour la Recherche Medicale
  11. Institut Sender

Ask authors/readers for more resources

The rare patients who are able to spontaneously control HIV replication in the absence of therapy show signs of a particularly efficient cellular immune response. To identify the molecular determinants that underlie this response, we characterized the T cell receptor (TCR) repertoire directed at Gag293, the most immunoprevalent CD4 epitope in the HIV-1 capsid. HIV controllers from the ANRS CODEX cohort showed a highly skewed TCR repertoire that was characterized by a predominance of TRAV24 and TRBV2 variable genes, shared CDR3 motifs, and a high frequency of public clonotypes. The most prevalent public clonotypes generated TCRs with affinities at the higher end of values reported for naturally occurring TCRs. The high-affinity Gag293-specific TCRs were cross-restricted by up to 5 distinct HLA-DR alleles, accounting for the expression of these TCRs in HIV controllers of diverse genetic backgrounds. Transfer of these TCRs to healthy donor CD4(+) T cells conferred high antigen sensitivity and polyfunctionality, thus recapitulating key features of the controller CD4 response. Transfer of a high-affinity Gag293-specific TCR also redirected CD8(+) T cells to target HIV-1 capsid via nonconventional MHC II restriction. Together, these findings indicate that TCR clonotypes with superior functions are associated with HIV control. Amplification or transfer of such clonotypes may contribute to immunotherapeutic approaches aiming at a functional HIV cure.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available